Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)@

Lead, Other Underwriters

Gross (US$M)

Post-Offering Market Cap (M)%

INITIAL OFFERINGS

Aegerion Pharmaceuticals Inc. (AEGR)¹

8/10/10

10/25

5S

$9.50

16.9

Leerink Swann
Lazard Capital (co-lead)
Needham & Co.
Canaccord Genuity

$47.5

$160.55

Anacor Pharmaceuticals Inc. (ANAC)²

9/10/10

11/24

12S

$5

26.6

Citigroup Global
Deutsche Bank (co-lead)
Cowen and Co. LLC
Wedbush PacGrow

$60

$133

Complete Genomics Inc. (GNOM)³

7/30/10

11/12

6S

$9

25.8

UBS Investment Bank
Jefferies & Co. (co-lead)
Robert W. Baird & Co. Inc.

$54

$232.2

Zealand Pharma A/S (Denmark; CSE:ZEAL)⁴

11/4/10

11/24

4.3S

DKK86 ($15.8)

N/A

Danske Bank A/S
Jefferies International Bryan, Garnier & Co.
SEB Enskilda
(all co-leads)

DKK372 ($67.9)

N/A

Total: $181 .9M

Number of IPOs in November: 3
Average value of November IPOs: $60.63M
Number of IPOs in 2010: 17
Total raised in IPOs in 2010: $1 , 140.46M
Average value of IPOs in 2010: $67. 1M

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)@

Lead, Other Underwriters

Gross (US$M)

Post-Offering Market Cap (M)%

FOLLOW-ON OFFERINGS

Avanir Pharmaceuticals Inc. (AVNR)⁵

9/23/09

11/16

20S

$4.40

113.9

Jefferies & Co. Inc.
Canaccord Genuity Inc.
Wedbush PacGrow Life
Summer Street Research
Merriman Capital

$88

$501.16

Cadence Phar-maceuticals Inc. (CADX)

9/17/09

11/8

11.5S

$8

62.1

Deutsche Bank Securities
Leerink Swann LLC
JMP Securities
Wedbush PacGrow Life Sciences
Canaccord Genuity Inc.

$92

$496.8

Cerus Corp. (CERS)

12/17/08

11/10

7.37U

$2.85

47.3

Jefferies & Co. Inc.
Robert W. Baird (co-lead)

$21

$134.8

Exact Sciences Corp. (EXAS)

9/7/10

11/4

10S

$6

50.5

Jefferies & Co. Inc.
Robert W. Baird (co-lead)
Lazard Capital Markets
Rodman & Renshaw

$60

$303

Micromet Inc. (MITI)⁶

11/2/09

11/12

9.9S

$7.30

90.9

Piper Jaffray

$72.27

$663.57

NeoStem Inc. (AMEX:NBS)⁷

5/19/10

11/17

6.34U

$1.45

64.1

Cowen and Co.
Maxim Group LLC
National Sec. Corp.

$9.2

$92.9

PharmAthene Inc. (AMEX:PIP)⁸

2/13/09

11/1

4.945S

$3.50

41.05

Roth Capital Partners

$17.3

$143.7

Somaxon Pharmaceuticals Inc. (SOMX)⁹

11/19/10

11/19

8.8S

$2.95

44.2

Piper Jaffray & Co.

$25.96

$130.39

Total: $385.73M

Number of follow-on offerings in November: 8
Average value of November follow-ons: $48.22M
Number of follow-on offerings in 2010: 66
Total raised in follow-ons in 2010: $5,260.27M
Average value of follow-ons in 2010: $79.7M

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal.

1 Aegerion's IPO was conducted in October, but was misclassified as a follow-on offering. Its overallotment option: 750,000 shares.

2 Anacor's overallotment option: 1 .8 million shares.

3 Complete Genomics' overallotment option: 900,000 shares.

4 Zealand Pharma's overallotment option: 650,407 shares.

5 Avanir's overallotment option: 3M shares.

6 Micromet's overallotment option: 1 .485M shares.

7 NeoStem offered 6.34M units, each containing one share and one warrant to purchase 0.5 shares at $1 .85. The company raised $9.8M in a concurrent direct offering, for total gross proceeds of $19M.

8 Includes PharmAthene's overallotment option: 645,000 shares.

9 Somaxon's overallotment option: 1 .32M shares.

Company (Symbol)#

Date Filed

Shares/Units (M)

Price

Shares Out

Lead, Other Underwriters (M)@

Gross (US$M)

INITIAL OFFERINGS

AcelRx Pharmaceuticals Inc. (ACRX)

11/12/10

N/A

N/A

N/A

Piper Jaffray
Canaccord Genuity
Cowen and Co.
JMP Securities

$86.25

Aldagen Inc. (ALDH)

10/29/09

Units

N/A

N/A

Boenning & Scattergood
Ladenburg Thalmann (co-lead)
National Securities Corp.

$46

Ambit Biosciences Corp. (AMBT)

11/5/10

N/A

N/A

N/A

J.P. Morgan
Credit Suisse (co-lead)
Leerink Swann
Wedbush PacGrow Life Sci.

$86.25

BG Medicine Inc. (BGMD)

1/29/10

N/A

N/A

N/A

Jefferies & Co.
UBS Investment Bank (co-lead)
Cowen & Co.
Baird

$86.25

BioLineRx Ltd. (BLRX)

9/24/10

N/A

N/A

N/A

JMP Securities
Oppenheimer & Co.

$40.25

Broadvector Ltd. (Australia; ASX)

9/8/10

42.5S

20 cents

N/A

N/A

$8.5

Cutanea Life Sciences Inc. (CTNA)1

11/5/10

2.3S

$6.50

3.9

Brean Murray, Carret & Co.
Rodman & Renshaw LLC (co-lead)

$14.95

Endocyte Inc. (ECYT)

8/17/10

N/A

N/A

N/A

RBC Capital Markets
Leerink Swann (co-lead)
Wedbush PacGrow Life Sciences

$86.25

Horizon Pharma Inc. (HZNP)

8/3/10

N/A

N/A

N/A

Jefferies & Co.
Piper Jaffray (co-lead)
JMP Securities
Lazard Capital Markets

$86.25

Med BioGene Inc. (Canada; MGBI)2

12/28/09

N/A

N/A

N/A

Rodman & Renshaw LLC

$24

Pacira Pharmaceuticals Inc. (PCRX)

11/1/10

N/A

N/A

N/A

Barclays Capital
Piper Jaffray (co-lead)
Wedbush Pacgrow Life Sci.
&Co.

$86.25

Prometheus RxDx Corp. (RXDX)

12/19/07

N/A

N/A

N/A

Goldman Sachs & Co.
Credit Suisse (co-lead)
SunTrust Robinson Humphrey
Cowen & Co.

$151.3

Quark Pharmaceuticals Inc. (TASE)

9/28/10

N/A

N/A

N/A

N/A

$20

Tranzyme Pharma Inc. (TZYM)

11/19/10

N/A

N/A

N/A

Citigroup Global Markets
BMO Capital Markets
Canaccord Genuity
Stifel Nicolaus Weisel

$75

Zogenix Inc. (ZGNX)3

9/8/10

6S

$12-$14

23.1

Wells Fargo Securities LLC
Leerink Swann LLC (co-lead)
Oppenheimer & Co.

$78

WITHDRAWN OR POSTPONED IPOS

Ikaria Inc. (IKAR)

5/13/10 (withdrawn 11/12/10)

8S

$12-$13

42.4

Goldman Sachs
Morgan Stanley (co-lead)
Credit Suisse
Lazard Capital
Cowen & Co.
Wedbush PacGrow
Soleil Securities

$100

Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange.

General shelf registration statements are not included until action is taken on the filing.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing.

1 Cutanea's overallotment option: 345,000 shares.

2 Med BioGene secured Rodman & Renshaw for an IPO in the U.S.

3 Zogenix's overallotment option: 900,000 shares.